EPISODE · Mar 3, 2023 · 38 MIN
Debate: Should Low Risk PV-MF Patients be Treated?
from EHA Unplugged · host European Hematology Association
Treatment of low-risk patients with polycythemia vera (PV) and myelofibrosis (MF) is still a matter of debate. Although traditionally these patients were managed exclusively with supportive treatment, more recent guidelines suggest the opportunity of identifying subgroups of patients eligible for cytoreduction. In this debate recorded during the EHA22 Annual Congress, experts Claire Harrison and Christen Lykkegaard Andersen support opposite statements on this topic, discussing the pros and cons of cytoreductive treatment in low-risk PV and MF patients, with the aid of representative clinical cases.Learn MoreIf you liked this podcast and would like to explore related content, you can check out our Polycythemia Vera course on the EHA Campus.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
What this episode covers
Treatment of low-risk patients with polycythemia vera (PV) and myelofibrosis (MF) is still a matter of debate. Although traditionally these patients were managed exclusively with supportive treatment, more recent guidelines suggest the opportunity of identifying subgroups of patients eligible for cytoreduction. In this debate recorded during the EHA22 Annual Congress, experts Claire Harrison and Christen Lykkegaard Andersen support opposite statements on this topic, discussing the pros and cons of cytoreductive treatment in low-risk PV and MF patients, with the aid of representative clinical cases.Learn MoreIf you liked this podcast and would like to explore related content, you can check out our Polycythemia Vera course on the EHA Campus.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
NOW PLAYING
Debate: Should Low Risk PV-MF Patients be Treated?
No transcript for this episode yet
Similar Episodes
Jun 24, 2026 ·20m
Jun 23, 2026 ·28m
Jun 23, 2026 ·10m
Jun 22, 2026 ·20m
Jun 19, 2026 ·70m